October 16, 2019
Expectations are growing for SGLT2 inhibitors as treatments for heart failure with preserved ejection fraction (HFpEF) after Novartis’ Entresto (sacubitril + valsartan) narrowly missed its primary goal in a PIII trial for that use. Boehringer Ingelheim/Eli Lilly’s Jardiance (empagliflozin) and...read more